Healthcare entity
Of the tracked stories, 1 of 2 also mention Alcon, the most common co-covered peer. Source depth averages 3.5 original sources per story, versus 3.1 across the same-window beat baseline. The 6 average consequence score is below the beat benchmark of 6.3 in the same window.
Last mentioned: Jun 30, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 1 of 2 also mention Alcon, the most common co-covered peer. Source depth averages 3.5 original sources per story, versus 3.1 across the same-window beat baseline. The 6 average consequence score is below the beat benchmark of 6.3 in the same window. Coverage clusters in medical-devices, which accounts for 1 of those 2, with the remainder spread across 1 other category. FTC appears in 2 tracked Healthcare stories from March 17, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 34 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering FTC. Shared-story counts are live from our verified record — not editorial picks.
Deal Termination
Alcon and LENSAR announce the end of the merger agreement due to FTC opposition.
FTC Investigation
The FTC intensifies its review of the merger, focusing on the ophthalmic laser market.
Merger Agreement
Alcon and LENSAR enter into a definitive agreement for Alcon to acquire LENSAR.
A major scientific consensus has emerged indicating that marijuana does not effectively alleviate anxiety or other mental health conditions. These findings challenge the clinical foundation of medical cannabis programs in 38 states and could trigger significant regulatory shifts.
Alcon has officially terminated its merger agreement with LENSAR, a leader in femtosecond laser technology, citing insurmountable opposition from the Federal Trade Commission (FTC). The collapse of the deal highlights increasing regulatory scrutiny over consolidation within the specialized medical device and ophthalmic surgery sectors.
FTC is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
